Pluristem is a biotechnology business based in the US. Pluristem shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem employs 153 staff and has a trailing 12-month revenue of around $234,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.67 |
|---|---|
| 52-week range | $0.66 - $0.80 |
| 50-day moving average | $1.19 |
| 200-day moving average | $1.76 |
| Wall St. target price | $3.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.46 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.67 from 2022-09-26
| 1 week (2023-09-14) | N/A |
|---|---|
| 1 month (2023-08-21) | N/A |
| 3 months (2023-06-21) | N/A |
| 6 months (2023-03-21) | N/A |
| 1 year (2022-09-23) | -4.29% |
|---|---|
| 2 years (2021-09-24) | -76.33% |
| 3 years (2020-09-25) | 9.66 |
| 5 years (2018-09-25) | 13.5 |
| Revenue TTM | $234,000 |
|---|---|
| Gross profit TTM | $23,000 |
| Return on assets TTM | -37.35% |
| Return on equity TTM | -86.55% |
| Profit margin | 0% |
| Book value | $1.18 |
| Market Capitalization | $32.3 million |
TTM: trailing 12 months
We're not expecting Pluristem to pay a dividend over the next 12 months.
Pluristem's shares were split on a 1:10 basis on 24 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem shares which in turn could have impacted Pluristem's share price.
Over the last 12 months, Pluristem's shares have ranged in value from as little as $0.6556 up to $0.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem's is 1.9127. This would suggest that Pluristem's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.